

Research highlights possible targets to help tackle Crohn's disease

June 17 2019



A scanning electron microscopy image of a macrophage, total magnification x5500. Credit: University of Plymouth



Affecting around 115,000 people in the UK alone, Crohn's Disease is a lifelong condition which sees parts of the digestive system become inflamed. There is no precise cure and causes are believed to vary. But one indicator of the condition—an abnormal reaction of the immune system to certain bacteria in the intestines—has had new light shed on it thanks to scientists at the University of Plymouth.

The research has focused on different types of cells called <u>macrophages</u>, which are part of our immune system and are found in most tissues, where they patrol for potential harmful organisms and destroy them.

In inflammatory diseases, like Crohn's, macrophages mediate the inflammatory destruction of the gut. Just how the tissue reacts (inflammation or suppression) is dependent on the type of macrophage cell present, and how it is stimulated—and scientists have been trying to get to the bottom of this.

The new research has shown how different types of macrophage—one type being pro-inflammatory and the other being antiinflammatory—exhibit quite different molecular mechanisms involved in switching off their functional behaviour when bacteria are present.

And this difference, as study author Dr. Andrew Foey explains, highlights the possibility of targeting and selectively suppressing the proinflammatory cells that drive diseases such as Crohn's Disease.

"This small step in understanding of differential off-signalling of macrophage type may go hand-in-hand with understanding the relapsing/remitting presentation of Crohn's Disease," he said. "It is suggestive of future research endeavours in targeting macrophage responses in the treatment of <u>inflammatory diseases</u>—and it's a really positive step."



The full study, entitled 'Macrophage subsets exhibit distinct E. coli-LPS tolerisable cytokines associated with the negative regulators, IRAK-M and Tollip' is available to view in the journal *PLOS ONE*.

The research was led by Dr. Andrew Foey with Dr. Khalid AlShaghdali and Ph.D. student Barbara Durante from the School of Biomedical Sciences at the University of Plymouth, in collaboration with Dr. Jane Beal, from the School of Biological and Marine Sciences.

Infection, Immunity and Inflammation is one of the key research themes in the Institute of Translational and Stratified Medicine (ITSMed) at the University of Plymouth.

More information: Khalid Al-Shaghdali et al, Macrophage subsets exhibit distinct E. coli-LPS tolerisable cytokines associated with the negative regulators, IRAK-M and Tollip, *PLOS ONE* (2019). DOI: 10.1371/journal.pone.0214681

Provided by University of Plymouth

Citation: Research highlights possible targets to help tackle Crohn's disease (2019, June 17) retrieved 2 May 2024 from https://medicalxpress.com/news/2019-06-highlights-tackle-crohn-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.